Hemophilia Gene Therapy Redux – The End of the Beginning?

Global Hemophilia Report · Jan 25, 2024 · 1h

Gene therapy for hemophilia A and B now exists as a licensed, prescribable treatment option for patients in certain countries; however, many questions and challenges remain. Senior advisor Dr. Donna DiMichele and patient-host Patrick James Lynch speak to global KOLs about the current state of hemophilia A and B gene therapies, both commercially and investigationally.

Contributors:

Lindsey A. George, MD

Margareth Ozelo, MD

Steven Pipe, MD

Senior Advisor: Donna DiMichele, MD

Hosted & Written by: Patrick James Lynch

Featured Advertiser:

Sanofi

Subscribe to the Global Hemophilia Report

Notes and…